New drug cocktail aims to fight returning brain tumors

NCT ID NCT05463848

Recruiting now Disease control Sponsor: L. Nicolas Gonzalez Castro, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of three drugs—pembrolizumab (immunotherapy), olaparib (a targeted therapy), and temozolomide (chemotherapy)—in people with recurrent glioblastoma, a type of brain tumor that has come back after initial treatment. The study will enroll 78 adults and measure how well the treatment controls tumor growth and boosts the immune response. Participants will receive the drugs before and after surgery to remove the tumor, allowing researchers to study the effects directly in the tumor tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (immunotherapy), Olaparib (PARP inhibitor), and Temozolomide (chemotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for recurrent glioblastoma, potentially extending survival and improving quality of life.
What could go wrong: This is an early-phase trial with only 78 participants. The drugs may cause side effects like fatigue, nausea, or immune-related reactions, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.